The ANXA4 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HAP1 cells with disrupted ANXA4, leading to loss of annexin A4. Generated by introducing Cas9 and guide RNA, this heterogeneous pool enables loss-of-function studies free of clonal selection bias. It serves as a versatile tool for functional genomics and mechanistic research.
The HAP1 host cell line is a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells from a male patient. Its haploid karyotype simplifies gene editing, enabling efficient CRISPR-mediated disruption and reducing genetic redundancy. HAP1 is widely used for functional genomics, including arrayed screens, and supports monolayer growth and various assay formats.
Annexin A4 (ANXA4) is a calcium-dependent phospholipid-binding protein that regulates membrane repair, exocytosis, and ion channel conductance. Transcriptionally controlled by SP1 and NF-??B, it is activated by calcium ions and binds phosphatidylserine. ANXA4 interacts with S100A6, phospholipase A2, and the actin cytoskeleton, and it collaborates with tissue factor and Factor VIIa in the coagulation cascade, influencing procoagulant phospholipid exposure. These activities govern cell adhesion, migration, and epithelial-mesenchymal transition, linking ANXA4 to cancer metastasis.
Disruption of ANXA4 in the near-haploid HAP1 background eliminates annexin A4 expression, creating a clean system for dissecting functions in phospholipid binding, ion channel regulation, and coagulation factor assembly. This model is particularly suited for live-cell imaging of membrane repair dynamics, calcium flux analysis, and quantitative assays of cell migration and invasion. The leukemic derivation offers a relevant context for studying hematopoietic adhesion and drug resistance, while the polyclonal nature avoids clonal bias.
This product supports a range of downstream applications, including calcium imaging to assess signaling changes, phosphatidylserine exposure assays for coagulation pathways, and migration/invasion assays for epithelial-mesenchymal transition research. Western blotting and immunofluorescence can validate altered expression of ANXA4 interactors such as S100A6. The polyclonal pool is compatible with pooled CRISPR screening and drug sensitivity profiling, making it a versatile tool for functional genomics and cancer pharmacology. For custom inquiries, contact Ascent Research.
